GALT vs. PHAR, COLL, IMNM, RAPP, SPRY, UPB, CRON, NBTX, VALN, and PGEN
Should you be buying Galectin Therapeutics stock or one of its competitors? The main competitors of Galectin Therapeutics include Pharming Group (PHAR), Collegium Pharmaceutical (COLL), Immunome (IMNM), Rapport Therapeutics (RAPP), ARS Pharmaceuticals (SPRY), Upstream Bio (UPB), Cronos Group (CRON), Nanobiotix (NBTX), Valneva (VALN), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.
Galectin Therapeutics vs. Its Competitors
Pharming Group (NASDAQ:PHAR) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.
Galectin Therapeutics has a net margin of 0.00% compared to Pharming Group's net margin of -2.19%. Galectin Therapeutics' return on equity of 0.00% beat Pharming Group's return on equity.
In the previous week, Pharming Group had 11 more articles in the media than Galectin Therapeutics. MarketBeat recorded 13 mentions for Pharming Group and 2 mentions for Galectin Therapeutics. Pharming Group's average media sentiment score of 0.19 beat Galectin Therapeutics' score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.
Pharming Group has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
Pharming Group has higher revenue and earnings than Galectin Therapeutics. Pharming Group is trading at a lower price-to-earnings ratio than Galectin Therapeutics, indicating that it is currently the more affordable of the two stocks.
0.0% of Pharming Group shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Pharming Group currently has a consensus price target of $30.00, suggesting a potential upside of 104.50%. Galectin Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 25.79%. Given Pharming Group's stronger consensus rating and higher probable upside, analysts clearly believe Pharming Group is more favorable than Galectin Therapeutics.
Summary
Pharming Group beats Galectin Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Galectin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GALT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding GALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Galectin Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:GALT) was last updated on 10/7/2025 by MarketBeat.com Staff
